DraftevicorePolicy N/A

Esophagogastroduodenoscopy (EGD) Coverage Policy

Customize your policy alerts

Sign up for all evicore policy alerts

Know when evicore releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage policy for Esophagogastroduodenoscopy (EGD) procedures under Cigna benefit plans administered by eviCore; provides guidance for medical necessity and coverage determinations for providers and medical reviewers.

Policy Summary

Payerevicore

PolicyEsophagogastroduodenoscopy (EGD) Coverage Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateNov 5, 2026

Next Review DateN/A

Key ActionDocument prior trials of empiric medical therapy and submit pertinent clinical records when requesting EGD authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2026-11-05Effective date

v2.0.2026Guideline version

3-52Document pages

~15Sections listed

6 months

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

DraftevicorePolicy N/A

Esophagogastroduodenoscopy (EGD) Coverage Policy

Customize your policy alerts

Sign up for all evicore policy alerts

Know when evicore releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payerevicore

PolicyEsophagogastroduodenoscopy (EGD) Coverage Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateNov 5, 2026

Next Review DateN/A

Key ActionDocument prior trials of empiric medical therapy and submit pertinent clinical records when requesting EGD authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2026-11-05Effective date

v2.0.2026Guideline version

3-52Document pages

~15Sections listed

6 months

Pernicious anemia interval

Medical Necessity and Coverage Criteria

EGD for Dyspepsia

EGD is medically necessary in individuals with dyspepsia when ONE of the following is met.

Primary indications

Age >=60: New-onset dyspepsia in individuals >=60 years
<60 with failed medical therapy: Individuals <60 years without red flag symptoms who have failed a 4-week trial of daily PPI (or appropriately dosed PCAB) OR failed an initial 'test and treat' H. pylori approach (eradication confirmed when applicable)
Any age with red flag: Any age with presence of any listed red flag symptoms or findings (see Red flag criteria)

Red flag criteria examples: Red flags include: family history of esophageal, gastric, or duodenal malignancy in a first‑degree relative; unintentional weight loss >=10 lbs or >=5% body weight over 6 months; signs of upper GI bleeding (melena, hematemesis) or laboratory evidence suggesting UGI bleed; iron‑deficiency anemia with supportive iron studies; dysphagia; odynophagia; persistent vomiting >=7 days; abnormal imaging suggesting organic disease of esophagus/stomach/duodenum; clinical suspicion of malignancy (weight loss, anorexia, cachexia, palpable mass/lymphadenopathy).

Typical GERD — Medically Necessary Criteria

EGD is medically necessary for typical GERD when either of the following groups is met:

Failure or recurrence after medical therapy: EGD is medically necessary if there is failure to respond to any of: an 8‑week once‑daily PPI trial, a 4‑week twice‑daily PPI trial, or a trial of appropriately dosed PCAB; OR return of typical GERD symptoms after discontinuation of provider‑directed appropriate anti‑secretory therapy of the same durations.

Alarm features accompanying GERD: EGD is medically necessary if any of the following accompany GERD symptoms: dysphagia; odynophagia; unintentional weight loss >=10 lbs or >=5% body weight over 6 months without identifiable reason; hematemesis; GI bleeding presumed upper GI by history/exam or lab data; iron‑deficiency anemia with supportive labs; persistent vomiting >=7 days.

Pre/post-procedure and other indications: EGD is medically necessary for evaluation of PPI‑dependent individuals being considered for endoscopic or surgical anti‑reflux procedures, for recurrent symptoms after anti‑reflux procedures, for placement of wireless pH monitoring, for one‑time repeat EGD after erosive esophagitis (LA B–D) following 8–12 weeks PPI to exclude Barrett's or dysplasia, and as a one‑time exam to exclude organic disease in symptoms considered functional when unresponsive or recurrent.

Extra-esophageal Reflux — Medically Necessary Criteria

EGD indications for extra‑esophageal reflux depend on presence of typical GERD symptoms and specialist evaluation:

Extra‑esophageal with typical GERD: When extra‑esophageal symptoms occur with typical GERD symptoms, EGD is medically necessary if there is failure to respond to an 8–12 week trial of twice‑daily PPI therapy.

Extra‑esophageal without typical GERD: When extra‑esophageal symptoms are not accompanied by typical GERD symptoms, EGD is medically necessary if either: (a) evaluation has been performed by the appropriate specialty (e.g., ENT, pulmonary, allergy) as indicated; OR (b) there is failure to respond to an 8–12 week trial of twice‑daily PPI therapy.

Dyspepsia/Upper Abdominal Symptoms — Guidance

Approach for dyspepsia and upper abdominal symptoms:

Test-and-treat for H. pylori: Use non‑invasive test‑and‑treat for H. pylori; if symptoms resolve, further diagnostics including EGD may not be medically necessary.

Age‑based EGD for dyspepsia: ACG/CAG recommend EGD for individuals aged >=60 years presenting with dyspepsia to exclude organic pathology. For individuals under 60, EGD is not medically necessary unless non‑invasive management fails or alarm symptoms arise.

Suspected pancreatic or biliary disease: Individuals with epigastric pain suggestive of pancreatic or biliary disease should undergo cross‑sectional imaging (ultrasound, CT, or MRI) before EGD.

Barrett's Esophagus — Screening & Surveillance

Screening and surveillance for Barrett's esophagus:

Screening eligibility: Screening EGD is medically necessary for individuals with chronic GERD symptoms (weekly for >=5 years) AND at least 3 of the following risk factors: age >=50 years, Caucasian race, male sex, obesity, history of tobacco smoking, or first‑degree family history of Barrett's esophagus or esophageal adenocarcinoma.

Surveillance: negative or nondysplastic BE: If endoscopy suggests Barrett's mucosa (>=1 cm) but biopsy is negative for intestinal metaplasia: one‑time repeat EGD in 1–2 years. For nondysplastic Barrett's (NDBE): repeat EGD every 3–5 years.

Indefinite, low‑ and high‑grade dysplasia: If indefinite for dysplasia: repeat EGD within 6 months. If low‑grade dysplasia and surveillance elected: EGD at 6 and 12 months then annually; if treated for low‑grade dysplasia: EGD at 1 and 3 years then every 2 years. If treated for high‑grade dysplasia or intramucosal/submucosal carcinoma: EGD at 3,6,12,18,24 months post‑eradication then annually thereafter.

Barrett's Esophagus: Surveillance and Post-Treatment

Barrett's esophagus surveillance and post‑treatment intervals:

BE_surveillance_if_LGD_surveillance_elected: If low‑grade dysplasia is found and endoscopic surveillance is chosen instead of treatment: repeat EGD at 6 and 12 months from diagnosis, then annually.

BE_post_treatment_LGD: If treated for low‑grade dysplasia: EGD at 1 and 3 years following complete eradication, then every 2 years thereafter.

BE_post_treatment_HGD_or_carcinoma: If treated for high‑grade dysplasia, intramucosal carcinoma, or submucosal carcinoma: EGD at 3, 6, 12, 18, and 24 months following complete eradication, then annually thereafter.

BE_recurrence: If recurrence of metaplasia or dysplasia is discovered: follow the surveillance intervals above.

Gastric Ulcer Surveillance

Surveillance EGD for gastric ulcer is medically necessary in the following situations:

Gastric ulcer surveillance indications: Surveillance EGD is medically necessary for any of: gastric ulcer endoscopically suspicious for malignancy even if biopsies benign after 8–12 weeks PPI and/or H. pylori therapy; persistent symptoms despite 8–12 weeks PPI/H.pylori therapy; gastric ulcer without clear etiology; index endoscopy without biopsy for medical reasons; gastric ulcer diagnosed radiologically; giant gastric ulcers (>3 cm) or refractory ulcers — EGD every 8–12 weeks until healed; history of Billroth II gastrectomy — one‑time EGD at 10–15 years post‑surgery.

Duodenal Ulcer Surveillance

Surveillance EGD for duodenal ulcer is medically necessary when any of the following are met:

Duodenal ulcer surveillance indications: Surveillance EGD is medically necessary for any of: persistent symptoms despite 8–12 weeks PPI and/or appropriate H. pylori therapy to rule out refractory or non‑peptic etiologies; giant duodenal ulcers (>2 cm) or refractory ulcers — EGD every 8–12 weeks until healing is documented.

Gastric Intestinal Metaplasia (GIM) Surveillance

Gastric intestinal metaplasia (GIM) surveillance criteria and intervals:

GIM with high‑grade dysplasia: If GIM with high‑grade dysplasia: repeat EGD immediately to confirm HGD, then EGD every 6 months.

GIM with low‑grade dysplasia: If GIM with low‑grade dysplasia: EGD every 12 months.

GIM without dysplasia in high‑risk individuals: EGD within 1 year for risk stratification, then every 3–5 years.

Incomplete intestinal metaplasia: Incomplete IM: EGD every 3–5 years.

Complete intestinal metaplasia: Complete IM: further surveillance EGD is not medically necessary.

General and Therapeutic EGD Indications

General and therapeutic EGD indications overview:

Symptom‑driven indications: Evaluation of documented dysphagia or odynophagia; persistent vomiting >=7 days; upper GI bleeding presumed by history/exam or labs; iron‑deficiency anemia presumed upper GI with supportive labs; assessment after caustic ingestion; evaluation for infection or immune‑mediated esophageal disease; EGD with small bowel biopsy for chronic diarrhea after appropriate workup.

Therapeutic interventions: Therapeutic EGD indications include removal of foreign bodies, polypectomy, treatment of bleeding lesions, placement of feeding/drainage tubes, dilation/stenting, endoscopic injections, and collection of tissue/fluid when clinically appropriate.

Intra‑operative and radiologic correlates: Intra‑operative evaluation of anatomic reconstructions and confirmation of histologic diagnosis of radiologic lesions involving the UGI tract are indications for EGD.

General/Therapeutic EGD indications

EGD is medically necessary when one or more of the following indications are met:

General indications: Intra‑operative evaluation of anatomic reconstructions; confirmation/histologic diagnosis of radiologic UGI lesions; suspected neoplastic lesions of esophagus/stomach/duodenum; gastric or esophageal ulceration; upper tract stricture/obstruction; sampling for suspected celiac disease or UGI infection; collection of gastric/duodenal fluid when appropriate; evaluation/treatment of gastric outlet obstruction; management of operative complications; removal of foreign bodies and feeding tube placement.

SIBO evaluation with EGD

EGD for suspected small intestinal bacterial overgrowth (SIBO) is covered when BOTH criteria are met:

SIBO duodenal fluid collection: 1) Breath testing (lactulose or glucose) is negative or inconclusive; AND 2) Clinical suspicion for SIBO remains high based on persistent or unexplained symptoms.

Alarm features warranting EGD

EGD is medically necessary when belching, bloating, and/or abdominal distension is accompanied by ANY of the following alarm features:

Alarm or high‑risk features: History of malignancy with propensity to metastasize to the abdomen; fever >=101°F; elevated WBC >10,000 or above lab upper limit; palpable mass of concern; overt or occult GI bleeding not obviously hemorrhoidal; moderate or severe abdominal tenderness; suspected complication of bariatric surgery; new onset symptoms at age >=60; unintentional weight loss >=10 lbs or >=5% body weight over 6 months without identifiable reason.

Gastric polyp treatment and surveillance

EGD is medically necessary for gastric polyps based on histology, size, dysplasia, and completeness of resection:

Adenomatous gastric polyps: Complete resection is supported upon histologic detection; after complete resection initial repeat EGD in 1 year, then surveillance every 3–5 years.

Hyperplastic gastric polyps: If unresected and no dysplasia: <10 mm — surveillance not medically necessary unless concerning features; >=10 mm — repeat EGD in 1 year. After resection: no dysplasia — repeat EGD in 1 year; dysplasia — repeat annually if requested; incomplete resection — repeat EGD in 1 year.

Fundic gland and adenomatous polyps: Fundic gland polyps <1 cm nondysplastic — EGD in 3 years; adenomatous polyps <1 cm nondysplastic or low‑grade dysplasia — EGD in 1 year; polyps >=1 cm — EGD in 1 year; incomplete or piecemeal resection — EGD at 6 months; high‑grade dysplasia — EGD in 3–6 months.

Duodenal/ampullary tumor follow‑up: Superficial non‑ampullary duodenal tumors — EGD 3 months after initial treatment then at 1 year if no recurrence. Ampullary tumors — EGD within 3 months, then at 6 and 12 months, then yearly for 5 years. If duodenal adenoma detected, colonoscopy is also medically necessary.

Atrophic gastritis surveillance (OLGA-based)

EGD surveillance intervals for atrophic gastritis are determined by OLGA stage and high‑risk features:

OLGA 0–1: Routine surveillance EGD is not medically necessary.

OLGA 2 with high‑risk features: EGD is medically necessary every 3 years when BOTH high‑risk features are present: (1) first‑degree relative with gastric cancer; AND (2) high‑risk race/ethnicity or born/emigrated from high‑incidence region.

OLGA 3–4: EGD is medically necessary every 2–3 years for OLGA stage 3 or 4; annual EGD is medically necessary when a first‑degree relative with gastric cancer is present. Autoimmune atrophic gastritis: EGD every 3 years.

Pernicious anemia

EGD is medically necessary for newly diagnosed pernicious anemia when diagnostic criteria are met:

Pernicious anemia diagnosis criteria: Diagnosis demonstrated by vitamin B12 below normal (<300 pg/mL) or elevated methylmalonic acid (MMA) AND one of: positive anti‑intrinsic factor antibodies; positive anti‑parietal cell antibodies; other lab findings consistent with B12 deficiency (elevated MCV and hypersegmented neutrophils) OR other lab findings consistent with gastric atrophy (elevated fasting serum gastrin or decreased serum pepsinogen I). EGD is medically necessary within 6 months of diagnosis.

Pernicious Anemia — Initial EGD

EGD for Pernicious Anemia — Covered when ALL of the following are met:

Pernicious anemia EGD criteria: 1) Diagnosis of pernicious anemia evidenced by vitamin B12 below normal (<300 pg/mL) or elevated MMA AND one of: positive anti‑intrinsic factor antibodies OR positive anti‑parietal cell antibodies OR other laboratory findings consistent with B12 deficiency (elevated MCV, hypersegmented neutrophils) OR laboratory findings consistent with gastric atrophy (elevated fasting serum gastrin or decreased pepsinogen I). 2) EGD performed within 6 months of diagnosis to confirm atrophic gastritis and rule out neoplasia. Follow‑up exams indicated only for development of new symptoms.

GIST Surveillance

GIST surveillance coverage conditions:

GIST <2 cm surveillance: Annual EGD surveillance is medically necessary for gastrointestinal stromal tumors (GISTs) smaller than 2 cm when surgical resection is not performed, to monitor for progression.

Gastric Neuroendocrine Neoplasm Surveillance

Post‑resection surveillance for gastric neuroendocrine neoplasms (g‑NEN):

g‑NEN post‑resection: After resection of gastric neuroendocrine neoplasms, surveillance EGD is medically necessary every 6–12 months for the first 3 years, then annually thereafter to detect recurrence or new neoplastic growths.

Gastric MALT Lymphoma Surveillance

Gastric MALT lymphoma surveillance schedule after H. pylori eradication:

Post‑H. pylori MALT surveillance: Following successful Helicobacter pylori eradication, EGD is medically necessary every 3 months for the first 2 years, then every 6 months thereafter (optimal long‑term interval not definitively established).

Bariatric Surgery — Pre-operative and Symptom-driven Post-operative EGD

Pre‑operative and symptom‑driven post‑operative EGD for bariatric surgery:

Bariatric pre/post EGD: Pre‑operative endoscopic evaluation is medically necessary. Post‑operative endoscopic evaluation is medically necessary for symptoms including nausea/vomiting, abdominal pain, post‑op GERD, dumping syndrome, diarrhea and nutritional deficiencies, endoscopic intervention for stenosis/foreign body/bezoars/fistula/leaks, bleeding or anemia, failure to lose weight, or weight gain after initial loss.

EGD for Known Upper GI Malignancy

EGD for known upper GI malignancy:

EGD for known malignancy: For known esophageal, gastric, or duodenal/small bowel malignancy, EGD is medically necessary as clinically indicated by the ordering provider for management of complications, treatment, evaluation of symptoms, and surveillance for recurrence.

Genetic Syndromes — EGD Surveillance

Syndrome‑specific EGD surveillance — age and interval criteria:

Hereditary cancer & polyposis syndromes surveillance: Syndrome‑specific EGD surveillance is medically necessary with specified start ages and intervals: Lynch syndrome beginning at age 30 every 2–3 years; Juvenile polyposis beginning at age 12 (annual if polyps); Peutz‑Jeghers beginning at age 8 (repeat every 2–3 years if polyps; if none, repeat at 18 then every 2–3 years); Hereditary Diffuse Gastric Cancer (CDH1) beginning at age 40 or 10 years before earliest family cancer up to every 6 months; Biallelic MMR deficiency annually from age 8; Tylosis annual from age 30; Cowden beginning at 15 repeat every 2 years; Classical FAP beginning at 20 (with exceptions); MUTYH‑associated polyposis beginning at 30; Li‑Fraumeni every 2–5 years starting at 25 (or 5 years before earliest family gastric cancer). Follow duodenal surveillance intervals by Spigelman staging when applicable.

EoE Diagnosis and Surveillance

EoE diagnosis and surveillance — initial and repeat criteria:

EoE initial EGD: Initial EGD is medically necessary for suspected EoE in individuals with PPI‑refractory GERD symptoms; dysphagia or food bolus obstruction; esophageal symptoms with atopic history; or esophageal symptoms with absolute eosinophil count >1500.

EoE repeat and surveillance EGD: Repeat EGD is medically necessary after 8 weeks of dietary or pharmacologic treatment to assess response, when initial histology was non‑diagnostic but suspicion remains, or after 1 year in specific diagnostic scenarios; any time significant symptoms recur while on previously effective treatment. Annual EGD surveillance (once per year) is medically necessary for evaluation of disease stability or progression and for endoscopic dilation of symptomatic fibrostenotic disease.

Celiac disease (EGD-1.18) — Medical necessity criteria

EGD is medically necessary in the following celiac‑related scenarios:

Positive serology: Individuals with elevated TTG IgA with normal total IgA, individuals with IgA deficiency and positive TTG IgG or deamidated IgG, or positive endomysial IgA antibody — EGD with small bowel biopsy is medically necessary to confirm celiac disease.

Negative serology but high suspicion: Individuals with negative serologies but high index of suspicion for celiac disease based on symptoms AND at least one risk factor (e.g., autoimmune conditions, first‑degree relative with celiac disease, Down/Turner/Williams syndromes, microscopic colitis) — EGD is medically necessary.

Individuals on gluten‑free diet: Seroconversion with gluten challenge OR significant symptoms after >=2 weeks on gluten‑containing diet with negative serologies plus permissive HLA — EGD may be medically necessary.

Known celiac disease indications: Inadequate biopsies on initial scope (one‑time repeat to obtain adequate biopsies); repeat EGD 2 years after starting gluten‑free diet to assess mucosal healing; persistent symptoms despite >=6 months compliance with gluten‑free diet — EGD with small bowel biopsy is medically necessary.

Inflammatory Bowel Disease (EGD-1.19) — Medical necessity criteria

EGD is medically necessary for suspected or established upper GI inflammatory bowel disease when conditions below are met:

Suspected upper GI Crohn's disease: Clinical features suggestive of Crohn's disease (chronic diarrhea, upper abdominal symptoms/dyspepsia, unintentional weight loss) AND elevated biomarkers (ESR/CRP/fecal calprotectin/lactoferrin) OR cross‑sectional imaging suspicious for Crohn's disease.

Established IBD indications: Active upper GI Crohn's disease for assessment/treatment decisions; new upper GI symptoms in Crohn's; suspected small bowel recurrence after resection; immunocompromised with upper GI symptoms; indeterminate colitis with upper GI symptoms; pre‑colectomy evaluation in ulcerative colitis; abnormal radiologic finding suggestive of upper GI disease; evaluation of pouch for Crohn's after IPAA.

Eosinophilic Esophagitis (EoE) — Role of EGD

Role of EGD in eosinophilic diseases:

EoE diagnosis and management role: Use EGD to visualize characteristic features (edema, furrows, rings, exudates, strictures) and obtain biopsies for histologic confirmation (>=15 eosinophils per high‑power field); also used to monitor treatment response and guide dilation of strictures. Balance use against procedural risks.

Esophageal Varices (GI.VE.001.20.A) — Screening and surveillance

Esophageal varices screening and surveillance criteria:

Initial varices screening: Initial EGD to screen for varices is medically necessary in any of: individuals with cirrhosis and evidence of decompensation; known or suspected cirrhosis with imaging evidence of portal hypertension; or compensated advanced chronic liver disease (cACLD) with noninvasive markers of clinically significant portal hypertension (LSM >=25 kPa OR LSM >=20 kPa with platelets <150,000/µL OR absence of reliable TE with clinical concern).

Surveillance if no varices: If no varices on initial EGD: repeat every 2 years if liver disease remains active; every 3 years if stable/quiescent.

Surveillance if varices present: If varices found: repeat EGD every 1 year if liver disease remains active; every 2 years if stable/quiescent; if decompensation occurs, surveillance every 1 year.

Bleeding varices management: Acute variceal bleeding requires urgent endoscopic intervention; after hemostasis a one‑time follow‑up EGD is medically necessary as determined by provider. After confirmed eradication, first EGD 3–6 months then every 6–12 months indefinitely.

These guidelines note that some procedures are not reviewed by eviCore for Cigna. Providers should refer to the current Cigna CPT code list to determine which high‑tech imaging procedures eviCore reviews for Cigna and to confirm applicability for a given benefit plan and date of service.

The extract available for review contains only the table of contents for the EGD guideline sections and therefore does not include detailed coverage criteria or prior authorization requirements in those pages. Operational reviewers should consult the full guideline sections cited in the table of contents for explicit criteria.

The referenced pages in this excerpt provide section headings and page references but do not include specific coverage criteria, exclusions, or medical necessity statements. Use the full guideline content for determinations.

Endomicroscopy is explicitly identified in the guideline as investigational and experimental at this time and is not supported as a standard indication in the current EGD guidance.

Routine use of EGD to evaluate extra‑esophageal manifestations of GERD (for example choking, chronic cough, asthma, hoarseness, laryngitis, chronic sore throat, or dental erosions) is not supported. The guideline states that most such individuals will not have endoscopic evidence of erosive esophagitis and that routine EGD for these presentations is not medically necessary in most cases.

EGD is not medically necessary to evaluate radiologic findings of an asymptomatic or uncomplicated sliding hiatal hernia (and similarly is not indicated for uncomplicated duodenal ulcers that have responded to therapy or for a deformed duodenal bulb when symptoms are absent or resolve with therapy).

Sequential or periodic EGD for surveillance of malignancy in individuals with fundic gland polyps or after prior gastric operations for benign disease is stated as not medically necessary unless other specific indications are present.

For newly diagnosed pernicious anemia, EGD is medically necessary within 6 months when diagnostic laboratory criteria are met. However, follow-up EGD is indicated only if new symptoms develop; routine repeat EGD solely for pernicious anemia without new clinical findings is not supported.

Chronic abdominal pain or diarrhea (>30 days) as solitary symptoms, without evidence of elevated serologic biomarkers associated with celiac disease, is not an indication for EGD. The guideline requires supportive serologic or other objective findings before endoscopic evaluation for celiac disease in such cases.

Within the pages referenced in this excerpt, no explicit coverage exclusions beyond the condition‑specific 'not medically necessary' statements are separately listed; reviewers should consult the detailed sections for any explicit exclusions.

This excerpt is a partial document window containing headers and table of contents entries and therefore is not directly applicable as a complete policy statement for operational coverage decisions without the full guideline text.

The guideline advises restricting routine abdominal imaging and upper endoscopy to individuals who have alarm features, recent worsening symptoms, or abnormal physical examination. For patients without such features, advanced testing and endoscopy should generally be deferred.

For individuals under age 60 with dyspepsia who respond to non‑invasive management (for example a 'test-and-treat' H. pylori strategy or an appropriate PPI/PCAB trial), the guideline states that EGD is not medically necessary unless non‑invasive therapy fails or alarm features develop.

After assessment for gastric intestinal metaplasia (GIM), further surveillance EGD is not medically necessary for complete IM, focal IM, or individuals not identified as high‑risk. High‑risk individuals or those with dysplasia have specified surveillance intervals described in the GIM guidance.

A repeat EGD solely to reassess a hiatal hernia is generally unnecessary; specifically, EGD is not medically necessary to evaluate asymptomatic or uncomplicated sliding hiatal hernia identified radiologically when the individual is asymptomatic or symptoms have responded to therapy.

The pages included in this fragment do not contain explicit 'not medically necessary' policy statements beyond the condition‑specific notes summarized elsewhere; reviewers should reference the full guideline for the detailed list of such statements.

Coding guidance in the referenced guideline clarifies that an endoscopic ultrasound (EUS) code includes an EGD and routine unbundling of EUS into separate EUS and diagnostic EGD codes is not supported. The coded content in this excerpt is neutral with respect to a single EGD code.

Coding Guidance and Clinical Thresholds

Coding guidance / notesmixed

EGD included in EUS coding

Coding for an EUS includes an EGD; routine unbundling of EUS into separate EUS and diagnostic EGD codes is not supported.

Vitamin B12 level threshold

Vitamin B12 thresholdSerum vitamin B12 below normal: < 300 pg/mL

Alternate markerElevated methylmalonic acid (MMA) may indicate B12 deficiency

Context for testingUsed to support diagnosis of pernicious anemia prompting EGD within 6 months

Fever threshold

Fever thresholdFever ≥101 °F (measured) as an alarm feature warranting EGD

Associated actionsConsider EGD when fever accompanies belching, bloating, or abdominal distension with other concerning findings

Authorization, Documentation, and Reviewer Guidance

Prior Authorization

Refer to Cigna CPT list for eviCore‑reviewed procedures

These guidelines include procedures that eviCore does not review for Cigna; providers must refer to the Cigna CPT code list to determine which high‑tech imaging/procedures are reviewed by eviCore for Cigna.

Prior Authorization

Prior authorization not specified in this excerpt

This extract contains only the table of contents and does not specify prior authorization requirements or affected billing codes for EGD procedures.

Prior Authorization

No prior‑auth code lists in this window

No prior authorization code lists or explicit prior‑auth requirements are included in the provided document window; the extract lists guideline sections only.

Background and Scope

Background: This document is an evidence‑based medical coverage policy developed by eviCore for use in interpreting Cigna benefit plans for Esophagogastroduodenoscopy (EGD). It is intended to guide medical directors and other health care professionals in making medical necessity and coverage determinations but is not a treatment guideline.

Key Definitions and Terms

CPT — definition and trademark notice

Copyright and liabilityAMA assumes no liability for the data contained in CPT; no fee schedules or relative values are included in the CPT book

Use guidanceRefer to the CPT and payer-specific code lists for coding and reimbursement determinations

EGD — abbreviation definition

EGD abbreviationEsophagogastroduodenoscopy (abbreviated EGD)

Scope purposeReferenced throughout the guideline as the procedure addressing esophagus, stomach, and duodenum

Policy Version and Revision History

2026-11-05policy_effectiveLatest

Policy version v2.0.2026 became effective on 2026-11-05.

Policy Summary

Payerevicore

PolicyEsophagogastroduodenoscopy (EGD) Coverage Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateNov 5, 2026

Next Review DateN/A

Key ActionDocument prior trials of empiric medical therapy and submit pertinent clinical records when requesting EGD authorization.

SourceLink

On This Page

Extensive IM: EGD every 3–5 years; if extensive IM plus first‑degree family history of gastric cancer then EGD every 1–2 years.

Focal IM or low‑risk individuals: Focal IM or individuals not identified as high‑risk: further surveillance EGD is not medically necessary.

Record measured temperature and clinical context in prior-authorization documentation

Elevated WBC threshold

Elevated WBC thresholdWhite blood cell count >10,000 or above the laboratory upper limit of normal as an alarm feature

Clinical implicationWarranting EGD when present with belching, bloating, or abdominal distension and other concerning signs

Documentation noteInclude laboratory report showing WBC and reference range when submitting for authorization

Unintentional weight loss threshold

Unintentional weight loss thresholdUnintentional weight loss ≥10 lbs OR ≥5% of body weight over 6 months (or less) qualifies as an alarm feature

ContextConsidered an alarm feature for dyspepsia and GERD prompting EGD evaluation

DocumentationDocument baseline weight, interval, and absence of identifiable reason when requesting EGD

Eosinophil count threshold

Histologic eosinophil threshold≥15 eosinophils per high-power field (hpf) on esophageal biopsy used to define EoE histologically

Peripheral criterionAbsolute eosinophil count (AEC) >1500 noted as a criterion for initial EGD consideration

Clinical relevanceThresholds support diagnosis of EoE and indications for initial or repeat EGD

Vitamin B12 laboratory threshold (repeated)

Primary B12 lab thresholdSerum vitamin B12 below normal: < 300 pg/mL

Alternative biochemical markerElevated methylmalonic acid (MMA) supports functional B12 deficiency

Supporting lab findingsMay include elevated MCV and hypersegmented neutrophils or positive anti-IF/anti-parietal cell antibodies

Liver stiffness measurement (Transient Elastography) thresholds

LSM < 10 kPaLiver stiffness measurement (LSM) <10 kPa by transient elastography effectively rules out compensated advanced chronic liver disease (cACLD)

LSM 10–20 kPaLSM 10–20 kPa represents an uncertain zone for cACLD; clinical correlation and serial monitoring recommended

LSM ≥ 20 kPaLSM ≥20 kPa suggests cACLD (higher likelihood of advanced fibrosis)

LSM ≥ 25 kPaLSM ≥25 kPa meets a noninvasive criterion for clinically significant portal hypertension (CSPH) used to guide varices screening

Duodenal biopsy sampling recommendation

Post-bulbar biopsiesObtain at least 4 biopsies from the post-bulbar (distal) duodenum

Duodenal bulb biopsiesObtain at least 1–2 biopsies from the duodenal bulb

Sensitivity rationaleCollecting ≥4 post-bulbar plus 1–2 bulb biopsies yields ~96% sensitivity for celiac disease due to patchy histology

Prior Authorization

Prior authorization not specified in section headings

The fragments shown are section headings and do not state prior authorization requirements for the referenced topics.

Prior Authorization

Authorize against guideline criteria and require pertinent clinical evaluation

Requests for EGD are evaluated against the guideline criteria and require submission of a pertinent clinical evaluation documenting new onset or change in symptoms.

Pertinent clinical evaluation should include detailed history & physical, appropriate labs, imaging, pathology and procedure reports, and reports from other treating providers.
For established individuals, a recent meaningful technological contact may suffice as the pertinent clinical evaluation.

Prior Authorization

Document failed therapy or qualifying alarm features on prior‑auth

Prior authorization should indicate failure of recommended empiric therapy durations or presence of qualifying indications such as alarm features when applicable.

Document failure of empiric anti‑secretory therapy per guideline durations (e.g., 4‑week daily PPI for dyspepsia; 8‑12 week PPI regimens for GERD/ulcer scenarios).
Document alarm features (dysphagia, odynophagia, significant weight loss, GI bleeding, iron‑deficiency anemia) when present.

Prior Authorization

Ensure indication matches listed medically‑necessary reasons

Prior authorization requests should document that the clinical indication matches a listed medically‑necessary indication for EGD (for example dysphagia, odynophagia, persistent vomiting ≥7 days, presumed upper GI bleeding, iron‑deficiency anemia with supportive labs).

Prior Authorization

Reference specific clinical evidence when requesting authorization

Clinical justification for authorization should reference meeting the specific listed criteria, such as diagnostic laboratory markers for pernicious anemia or negative/inconclusive breath testing with persistent high suspicion for SIBO.

For pernicious anemia: reference vitamin B12 <300 pg/mL or elevated MMA and supporting antibody/lab findings.
For SIBO: document breath test results (negative or inconclusive) and ongoing clinical suspicion.

Prior Authorization

Prior‑auth recommended for initial or repeat EGD in EoE

Prior authorization is recommended/required when seeking coverage for initial or repeat EGD to diagnose or surveil eosinophilic esophagitis (EoE) according to the policy's diagnostic and timing criteria.

Initial EGD indicated for PPI‑refractory GERD, dysphagia/food bolus obstruction, atopic history, or absolute eosinophil count >1500.
Repeat EGD indicated after 8 weeks of dietary/pharmacologic therapy or per surveillance intervals (including annual surveillance in established EoE).

Prior Authorization

Document cirrhosis/portal‑hypertension evidence for varices screening

EGD is medically necessary to screen for esophageal varices in individuals with cirrhosis and decompensation, imaging evidence of portal hypertension, or cACLD with noninvasive markers of clinically significant portal hypertension; providers should document these findings when requesting EGD.

Document decompensation features (ascites, encephalopathy, variceal bleeding) or imaging evidence of portal hypertension (portosystemic collaterals, splenomegaly).
Noninvasive CSPH markers include TE LSM ≥25 kPa or LSM ≥20 kPa with platelets <150,000/µL.

Prior Authorization

No prior‑auth codes listed in these reference pages

No prior authorization codes or requirements are specified in the reference pages included in this extract.

Prior Authorization

Prior‑auth criteria not included in references

No prior authorization criteria are included in the references fragment provided here.

Step Therapy

No step therapy rules in these chunks

No step therapy requirements are included in the provided document chunks.

Step Therapy

No step therapy in these fragments

No step therapy rules are present in these reference fragments.

Step Therapy

Require 4‑week PPI (or PCAB) trial before EGD for <60 dyspepsia

For dyspepsia in individuals under age 60 without red flag features, EGD is appropriate only after failure of a 4‑week trial of daily PPI (or appropriately dosed PCAB) or after failure of a 'test and treat' H. pylori strategy with confirmation of eradication when applicable.

PPI should be taken daily unless there is documented allergy or intolerance.
H. pylori eradication should be confirmed 4 weeks after therapy completion by non‑invasive testing when applicable.

Step Therapy

Document anti‑secretory therapy trial duration before EGD for GERD

Many GERD indications require documentation of a trial of anti‑secretory therapy of specified duration (e.g., 8‑week once‑daily PPI, 4‑week twice‑daily PPI, or appropriately dosed PCAB) prior to approving EGD.

Return of typical GERD symptoms after discontinuation of appropriately directed anti‑secretory therapy of these durations also supports medical necessity.

Step Therapy

Expect 8–12 week medical therapy trial before ulcer surveillance EGD

For surveillance of gastric or duodenal ulcers, a trial of daily PPI and H. pylori therapy when applicable for 8–12 weeks is expected prior to surveillance EGD to document persistent symptoms or nonhealing ulcers.

Giant or refractory ulcers may require repeat EGD every 8–12 weeks until healing is documented.

Step Therapy

Require non‑endoscopic SIBO testing before EGD aspirate collection

For suspected small intestinal bacterial overgrowth (SIBO), perform non‑endoscopic testing (breath testing or dietary trials) first; EGD with duodenal fluid collection is indicated only when breath testing is negative or inconclusive and clinical suspicion remains high.

Step Therapy

PPI trial and timed repeat EGD considerations for suspected EoE

For suspected EoE, initial management with a PPI may be relevant because more than one‑third of patients respond; repeat EGD timing for assessment of treatment response is specified (e.g., after 8 weeks of therapy) and annual surveillance is described for established disease.

Repeat EGD is medically necessary after 8 weeks of dietary or pharmacologic treatment to assess response.
Annual EGD surveillance is medically necessary for evaluation of disease stability or progression in established EoE.

Documentation Required

Document rationale when opting for endoscopy rather than non‑endoscopic EoE management

When choosing EGD for EoE, consider non‑endoscopic management and balance procedural risks; document the rationale for selecting endoscopy over alternative pathways.

Step Therapy

No step therapy rules in these references

No step therapy rules are provided in the reference pages included in this extract.

Step Therapy

No step therapy in references

No step therapy requirements are included in the references section of this extract.

Note

Coverage policy is guidance — verify member benefit plan

Use this coverage policy as an interpretive guide, but verify the member's specific benefit plan documents and any applicable laws/regulations because coverage determinations depend on those terms.

Documentation Required

No documentation rules in TOC fragments

No documentation submission requirements are present in the table‑of‑contents fragments shown.

Documentation Required

No documentation requirements in this excerpt

No documentation requirements are present in the provided excerpt; the content is limited to section headings and page references.

Documentation Required

Include complete H&P, labs, imaging, pathology and procedure reports

Submit pertinent medical records with authorization requests, including a detailed history & physical, relevant laboratory studies, imaging, pathology and prior procedure reports, and reports from other treating providers.

For established individuals, a recent meaningful technological contact (telehealth, telephone, electronic message) since symptom onset/change may suffice.
If records lack sufficient detail to understand current clinical status, requests may be denied.

Documentation Required

Document prior empiric therapy, alarm features, and specialty evaluations

Document trials of empiric medical therapy (agent and duration), presence of alarm features (dysphagia, odynophagia, weight loss, GI bleeding, iron‑deficiency anemia), specialty evaluations for extra‑esophageal symptoms, and prior anti‑reflux procedural history when requesting EGD.

Documentation Required

Include pathology confirmation and dysplasia grade (second review if indefinite)

Provide pathology confirmation and documentation of dysplasia grade for Barrett's esophagus and GIM; for pathology that is suggestive or indefinite for dysplasia, include second pathologist confirmation when suggested.

Document risk factors (family history, race/ethnicity, country of birth) when submitting for GIM surveillance.

Documentation Required

Document index biopsy status or reason biopsy not performed

For surveillance after gastric ulcer, document the initial biopsy status or the clinical reason a biopsy was not performed (e.g., active bleeding, coagulopathy) to justify surveillance timing.

Documentation Required

Document breath test results and persistent symptoms for SIBO EGD

When using EGD for SIBO workup or persistent small‑bowel symptoms, document non‑invasive breath test results (negative or inconclusive) and persistent clinical symptoms to support endoscopic duodenal fluid collection.

Document rationale that non‑endoscopic testing was negative/inconclusive and clinical suspicion remains high.

Documentation Required

Document B12 <300 pg/mL or elevated MMA and supporting antibodies for PA

For newly diagnosed pernicious anemia, document diagnostic laboratory evidence including vitamin B12 <300 pg/mL or elevated methylmalonic acid (MMA) and supporting anti‑intrinsic factor or anti‑parietal cell antibodies or other consistent laboratory findings.

Evidence of pernicious anemia and timing (EGD within 6 months of diagnosis) should be included in the request.

Documentation Required

Specify pre‑op vs symptom‑driven post‑op indication and list symptoms for bariatric patients

For bariatric surgery patients, document whether the EGD is pre‑operative evaluation or post‑operative symptom‑driven, and list the specific symptoms prompting EGD (e.g., nausea/vomiting, abdominal pain, post‑op GERD, dumping syndrome, bleeding/anemia, failure to lose weight).

Documentation Required

Document duodenal biopsy adequacy or prior inadequate biopsies for repeat EGD

Document initial duodenal biopsy adequacy (at least four post‑bulbar biopsies and 1–2 from the bulb) and, if requesting a repeat EGD for celiac evaluation, include documentation of prior inadequate biopsies to justify one‑time repeat scope.

Adequate sampling details support medical necessity for repeat biopsy when prior sampling was insufficient.

Documentation Required

References section — no submission rules

This section of the document contains the bibliographic references and does not include operational documentation or submission rules.

Denial Risk

Coverage depends on benefit plan terms and applicable laws

Coverage determinations are governed by the member's applicable benefit plan document, laws/regulations, and collateral materials; the coverage policy is interpretive and may be superseded by the plan terms.

Denial Risk

No denial triggers in TOC pages

The provided pages are a table of contents and do not include explicit denial triggers or authorization steps.

Denial Risk

No explicit authorization or denial criteria here

This window contains section headings only and does not state explicit authorization or denial triggers.

Denial Risk

No authorization/denial criteria in headings

The fragments shown are table‑of‑contents headings and do not include authorization or denial criteria.

Denial Risk

Denial risk for insufficient documentation

Requests may be denied if submitted medical records do not provide sufficiently detailed information to understand the individual's current clinical status and establish medical necessity.

Denial Risk

Denial risk if prior medical therapy trials not documented

Failure to document prior trials of specified empiric medical therapy (for example 8‑week once‑daily PPI, 4‑week twice‑daily PPI, or appropriately dosed PCAB when indicated for GERD) may lead to denial.

Denial Risk

Denial risk for Barrett's screening without required GERD duration and risk factors

Screening EGD for Barrett's esophagus may be denied if chronic GERD symptoms for ≥5 years plus at least three listed risk factors are not documented.

Required risk factors include age ≥50, Caucasian race, male sex, obesity, tobacco history, or family history of Barrett's/EAC in a first‑degree relative.

Denial Risk

Denial risk for missing 8–12 week PPI trial documentation

Failure to document an appropriate trial of daily PPI therapy for 8–12 weeks (or documented allergy/intolerance and alternative therapy) when indicated for ulcer surveillance or refractory reflux may affect approval.

Denial Risk

Denial risk for missing duodenal ulcer therapy trial documentation

Lack of documentation of persistent symptoms after 8–12 weeks of PPI and/or H. pylori therapy when claiming surveillance for duodenal ulceration may trigger denial.

Denial Risk

Denial risk: EGD not indicated for asymptomatic/uncomplicated radiologic findings

EGD is not medically necessary to evaluate radiologic findings for asymptomatic or uncomplicated sliding hiatal hernia, uncomplicated duodenal ulcer that has responded to therapy, or deformed duodenal bulb when symptoms are absent or respond to therapy.

Denial Risk

Denial risk if pernicious anemia labs not provided

Failure to document pernicious anemia diagnosis with supporting laboratory evidence (e.g., vitamin B12 <300 pg/mL or elevated MMA with supporting antibody or laboratory findings) may lead to denial of EGD for this indication.

Denial Risk

Denial risk for celiac‑related EGD without supporting biomarkers

EGD is not indicated for chronic abdominal pain or diarrhea (>30 days) as sole symptoms without elevated biomarkers associated with celiac disease; lacking such biomarkers when claiming celiac‑related EGD may lead to denial.

Denial Risk

References only — no authorization/denial instructions

These reference pages are bibliography and do not include authorization or denial instructions.

Document contextEGD guidelines and related sections are presented across the document for clinical indications and surveillance

Dyspepsia definition

Dyspepsia definitionPredominant epigastric pain lasting at least one month

Associated symptomsOften associated with epigastric fullness, nausea, vomiting, early satiety, or heartburn when epigastric pain is the primary concern

EGD indication contextEGD is medically necessary for dyspepsia when one of listed criteria (e.g., age ≥60, failed empiric therapy, or red flags) is met

GERD definition

GERD definitionGastroesophageal reflux disease (GERD) is presence of symptoms or mucosal damage from abnormal reflux of gastric contents into the esophagus

Typical vs atypicalTypical GERD includes heartburn and/or regurgitation; atypical/extra-esophageal includes chronic cough, hoarseness, and chest pain

Clinical relevanceDefinitions underpin indications for EGD in typical and extra‑esophageal presentations

Barrett's esophagus (BE)

Endoscopic appearanceBarrett's esophagus (BE) requires salmon‑colored mucosa with intestinal metaplasia of at least 1 cm in length

Surveillance intervalsIf pathology is negative but endoscopy suggests BE, repeat EGD in 1–2 years; nondysplastic BE surveillance every 3–5 years; dysplasia-based intervals shorter

Diagnostic confirmationBiopsy confirmation of intestinal metaplasia is required for diagnosis; dysplasia grading guides management

Gastric intestinal metaplasia (GIM)

GIM definitionGastric intestinal metaplasia is replacement of normal gastric epithelium with intestinal‑type epithelium

ClassificationClassified by extent (focal vs extensive) and completeness (complete vs incomplete), which influences surveillance frequency

EtiologyCommonly arises from chronic gastric inflammation such as H. pylori infection or autoimmune metaplastic atrophic gastritis

OLGA staging

OLGA staging systemOLGA stratifies atrophic gastritis into stages 0–IV based on severity and distribution of atrophy

Surveillance guidanceHigher OLGA stages (III–IV) indicate increased gastric cancer risk and support periodic EGD surveillance (e.g., every 2–3 years)

PersonalizationOLGA II management individualized based on additional risk factors (family history, incomplete IM, multifocal lesions)

Pernicious anemia (PA)

Pernicious anemia definitionPernicious anemia: vitamin B12 deficiency due to intrinsic factor/parietal cell autoimmunity

Supporting lab criteriaDiagnosis supported by low serum B12 (<300 pg/mL), elevated MMA, hypersegmented neutrophils, elevated MCV, and anti‑parietal cell or anti‑intrinsic factor antibodies

EGD timingEGD is medically necessary within 6 months of new pernicious anemia diagnosis to confirm atrophic gastritis and exclude neoplasia

Pernicious anemia (PA) — autoimmune gastritis context

Autoimmune gastritis mechanismAutoimmune gastritis–related intrinsic factor deficiency leads to impaired B12 absorption and pernicious anemia

Laboratory supportLow serum B12 (<300 pg/mL) or elevated MMA plus anti‑IF or anti‑parietal cell antibodies support the diagnosis

EGD roleEGD with biopsies is indicated to confirm atrophic gastritis and rule out neoplasia in newly diagnosed PA

Eosinophilic esophagitis (EoE)

EoE definition (clinical)Eosinophilic esophagitis (EoE) is a chronic immune/antigen‑mediated esophageal disease characterized by esophageal dysfunction (dysphagia, food impaction, chest pain) and association with atopic conditions

Histologic hallmarkHistologic eosinophil‑predominant inflammation (≥15 eosinophils per high‑power field) confirms diagnosis

Role of EGDEGD is used to visualize features (rings, furrows, exudates, strictures) and obtain biopsies for diagnosis and monitoring

EoE definition (repeated)

EoE restatementChronic, immune/antigen‑mediated esophageal disease with symptoms of esophageal dysfunction and histologic eosinophil‑predominant inflammation (≥15 eos/hpf)

Clinical featuresIncludes dysphagia, food impaction, PPI‑refractory chest pain, and association with atopic disease

Management noteMore than one‑third of esophageal eosinophilia cases respond to PPI therapy (PPI‑REE), so medical trial may be relevant prior to repeat EGD when appropriate

Celiac disease diagnostic testing

Celiac serologic testingSerologic testing with TTG IgA while on a gluten‑containing diet and measurement of total IgA; if IgA deficient, use TTG IgG or DGP IgG

Endoscopic confirmationFollow positive serology with EGD and duodenal biopsies to confirm histologic injury

Biopsy samplingObtain ≥4 biopsies from distal duodenum and 1–2 from duodenal bulb due to patchy histology

Clinically significant portal hypertension (CSPH)

CSPH definitionClinically significant portal hypertension (CSPH) is associated with hepatic venous pressure gradient (HPVG) >10 mmHg; noninvasive surrogates guide varices screening

Noninvasive surrogatesLSM thresholds (e.g., ≥25 kPa or ≥20 kPa with platelets <150,000/µL) and platelet counts are used to decide varices screening via EGD

Screening implicationUse noninvasive markers to identify individuals with cACLD/CSPH who require initial EGD for variceal assessment

Guideline version

Guideline versionv2.0.2026

Effective dateEffective 2026-11-05 (policy/guideline context)

UsageVersion identifier used throughout the document for reference and updates